HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

Hutchmed

HUTCHMED (China) Limited (Nasdaq/LON:​HCM; HKEX:​13) has announced that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2025 World Conference on Lung Cancer (WCLC) taking place on September 6-9, 2025 in Barcelona, Spain, and the Chinese Society of Clinical Oncology (CSCO) Annual Meeting 2025, taking place on September 10-14, 2025 in Jinan, China.

Updated analysis from savolitinib’s SACHI, SAVANNAH and a Phase IIIb confirmatory study in non-small cell lung cancer (NSCLC) patients will be presented at WCLC 2025. Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (TKI) being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Details of the WCLC 2025 presentations are as follows:

Abstract titlePresenter / Lead authorPresentation details

SPONSORED STUDIES
 
SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC Christina Baik, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA MA03.03
Mini Oral: New Advances in Circulating BiomarkersRoom 06
Sunday, September 7, 20253:15 – 4:30PM CEST
Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy Yongfeng Yu, Shanghai Chest Hospital, Shanghai, China P3.12.48
Poster: Metastatic NSCLC – Targeted Therapy
Tuesday, September 9, 2025
Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation EGFR-TKI Failure: SACHI Study Insights Lijuan Chen, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China P3.12.64
Poster: Metastatic NSCLC – Targeted Therapy
Tuesday, September 9, 2025 
Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs Silvia Novello, University of Turin, San Luigi Hospital, Turin, Italy PT2.12.04e
Poster: Metastatic NSCLC – Targeted Therapy
Monday, September 8, 2025
 INVESTIGATOR-INITIATED STUDIES
Efficacy and Safety of Surufatinib, Durvalumab in Combined with Chemotherapy as First-line Treatment of Extensive-stage Small-cell Lung CancerHui Zhang/ Ying Hu, Beijing Chest Hospital, Beijing, ChinaP3.13.22
Poster: Small Cell Lung Cancer and Neuroendocrine Tumors
Tuesday, September 9, 2025

Clinical data of HMPL-653, a novel, selective and potent CSF-1R inhibitor, from a first-in-human Phase I study in patients with tenosynovial giant cell tumor in China will be presented for the first time at the CSCO Annual Meeting 2025. Details of the CSCO Annual Meeting 2025 presentations are as follows:

Abstract titlePresenter / Lead authorPresentation details

SPONSORED STUDIES
 
A first-in-human phase I study of HMPL-653, a CSF-1R inhibitor, in patients with tenosynovial giant cell tumorXiaohui Niu  25297
Oral Session
Friday, September 12, 2025
15:00 – 15:12PM HKT
 INVESTIGATOR-INITIATED STUDIES 
Fruquintinib Plus Serplulimab as First-Line Therapy in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (nccRCC): Updated Efficacy and Safety from a Multicenter, Single-Arm TrialJiwei Huang/ Wei Xue 23258
Oral Session
Thursday, September 11, 2025
16:50 – 17:15PM HKT
Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): updated data from a single-arm, phase II clinical trialTianzhu Qiu/ Yanhong Gu23766
Oral Session
Friday, September 12, 2025
11:20 – 12:00 noon HKT
Fruquintinib plus chemotherapy as second-line therapy in metastatic colorectal cancer: a multicenter, open-label, phase II clinical trialYongshun Chen 22084Poster Session
Efficacy and Safety of Neoadjuvant Fruquintinib plus Toripalimab and Short-Course Radiotherapy (SCRT) for Locally Advanced Rectal Cancer: Updated Results from a Phase II Clinical TrialZhiping Li 21915
Abstract
Fruquintinib combined with chemotherapy as first-line treatment for advanced metastatic colorectal cancer: a propensity score‑matched comparison of efficacy between a prospective single-arm cohort and a retrospective observational cohortFuxiang Zhou 23550
Abstract
Efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and chidamide armMiaomiao Gou23591
Abstract
Phase ll Clinical Study of Surufatinib Combined with Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerMiaomiao Gou23610
Oral Session
Friday, September 12, 2025
16:53 – 16:59PM HKT
A single-arm, Phase Ib/II trial of surufatinib plus KN046 and gemcitabine and nab-paclitaxel as first-line treatment for unresectable advanced pancreatic cancerWenquan Wang/ Liang Liu 23783
Oral SessionThursday, September 11, 2025
16:20 – 16:35PM HKT
Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: a prospective, randomized, controlled trialDan Cao22652
Poster Session
Surufatinib in patients with soft tissue myeloma who have failed first-line standard chemotherapy or anlotinib: a multicenter, prospective, two-cohort, phase II clinical studyYuhong Zhou/ Xi GuoP80
Poster Session
Efficacy and Mechanistic Study of the NASCA Regimen (Surufatinib Combined with Camrelizumab, Nab-Paclitaxel, and S‑1) in Advanced Pancreatic Cancer Patients with Liver MetastasisGuanghai Dai/ Ru Jia22309
Abstract
A Phase II, Single-Arm Study of Surufatinib Combined with Zimberelimab and Nab-Paclitaxel in Patients with Advanced Triple‑Negative Breast Cancer: Data UpdateCaixia Wang 23679
Abstract
Efficacy and safety of surufatinib combined with gemcitabine, cisplatin and immune checkpoint inhibitor for the treatment of unresectable locally advanced or metastatic intrahepatic cholangiocarcinomaXuetao Shi/ Jingtao Zhong24133
Abstract
Efficacy and Safety of Surufatinib in Patients with Neuroendocrine Neoplasms: A Multicenter Retrospective StudyJiang Long24294
Abstract

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

    HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653.

    HUTCHMED CEO Dr Weiguo Su takes leave of absence

    HUTCHMED (China) has announced that Chief Executive Officer Dr Weiguo Su will take a leave of absence due to health reasons. The Board has appointed Johnny Cheng, the company’s Chief Financial Officer and Executive Director, as Acting CEO while continuing in his CFO role.

    HUTCHMED completes enrollment for phase III SANOVO lung cancer study

    HUTCHMED has completed patient enrollment for its Phase III SANOVO trial evaluating ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) as a first-line treatment for certain EGFR-mutated, MET-overexpressed non-small cell lung cancer patients.

    HUTCHMED showcases new oncology data at ASCO 2025

    HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors.

    HUTCHMED completes Savolitinib trial enrollment

    HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET amplification.

      Search

      Search